Magazine Article | October 3, 2022

How To Navigate Drug Repurposing And Bridging Studies

Source: Life Science Leader

By Barbara Binzak Blumenfeld

Drug repurposing is not a new concept. However, the COVID-19 pandemic prompted many companies to consider whether a drug approved for one indication had a place in doctors’ and pharmacists’ armamentarium of treatment options for an emerging disease. The antiviral medication Remdesivir, originally developed to treat hepatitis C, was one of the most high-profile repurposed drugs to emerge during the pandemic, receiving both an emergency use authorization and an approval from the FDA for the treatment of COVID-19 patients.

access the Magazine Article!

Get unlimited access to:

Trend and Thought Leadership Articles
Case Studies & White Papers
Extensive Product Database
Members-Only Premium Content
Welcome Back! Please Log In to Continue. X

Enter your credentials below to log in. Not yet a member of Life Science Leader? Subscribe today.

Subscribe to Life Science Leader X

Please enter your email address and create a password to access the full content, Or log in to your account to continue.


Subscribe to Life Science Leader